FORM 4 Check this box if no

longer subject to

may continue. See

Instruction 1(b).

(Print or Type Responses)

Section 16. Form 4 or Form 5 obligations

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person – Tepper Mark				2. Issuer Name and Ticker or Trading Symbol Corbus Pharmaceuticals Holdings, Inc. [CRBP]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
(Last) (First) (Middle) C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE				3. Date of Earliest Transaction (Month/Day/Year) 01/07/2016												
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person _Form filed by More than One Reporting Person						
NORWOOD, MA 02062 (City) (State) (Zip)				Table I - Non-Derivative Securities Acqui						ıired, E	ired, Disposed of, or Beneficially Owned					
1.Title of Secur (Instr. 3)	rity	I	Date Month/Day/Year)	2A. Deem Execution any (Month/D	n Date	(Inst	e	(A	Securities Ad or Disposed nstr. 3, 4 and (A) comount (D)	d of (D) 5)	Owne Transa (Instr.		ecurities Berng Reported	C F D o.	wnership of Be irect (D) Ov Indirect (Ir	eneficial wnership
Reminder: Repo	ort on a sepa	rate line for each cla	Table II - I	Derivative	Secui	rities Ac	quire	Persons in this for a currer		require MB cont	ed to re trol nu	espond ι ımber.		on containe form displa		74 (9-02)
Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Date Exe (Month/Day/Year) any	3A. Deemed Execution Date, if	if Transaction De Code See ar) (Instr. 8) Ac or of (In		Number of erivative		6. Date Exercisable and		d 7. Ti of U Secu	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Derivative Security (Instr. 5)	Securities Beneficially Owned Following Reported Transaction(s)	Derivative Security: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)		Date Exercisal	Expiration le Date	Title	•	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
				Couc		()	\ /									

Reporting Owners

Percenting Occurs Name / Additions	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Tepper Mark C/O CORBUS PHARMACEUTICALS HOLDINGS, INC 100 RIVER RIDGE DRIVE NORWOOD, MA 02062			President and CSO			

Signatures

/s/ Mark Tepper	01/11/2016
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on January 7, 2017, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on February 7, 2017.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.